Quviviq, a new insomnia drug, has been approved by the FDA, potentially rivaling existing medications such as Belsomra and Dayvigo. The new treatment is part of a class of medications known as dual orexin receptor antagonists, which are used to treat insomnia. Comparisons are being made between Quviviq and other insomnia medications, including Belsomra and Ambien, in terms of similarities, differences, and potential side effects.